-
公开(公告)号：US20220211812A1
公开(公告)日：2022-07-07
申请号：US17573238
申请日：2022-01-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US20210196791A1
公开(公告)日：2021-07-01
申请号：US17198939
申请日：2021-03-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号：US10947297B2
公开(公告)日：2021-03-16
申请号：US15819925
申请日：2017-11-21
Applicant: Bristol-Myers Squibb Company
Inventor： Ray Camphausen , Jonathan H. Davis , Sharon T. Cload , Fabienne M. Denhez , Amna Saeed-Kothe , Dasa Lipovsek , Ching-Hsiung Frederick Lo , Chee Meng Low , Bowman Miao , Tracy S. Mitchell , Rex A. Parker , Ginger C. Rakestraw , Katie A. Russo , Doree F. Sitkoff
IPC: A61K39/00 , A61K39/44 , C07K4/00 , C07K14/00 , C07K14/78 , A61K38/39 , C12N9/64 , A61K47/60 , A61K47/54 , C07K16/18 , C07K16/40
Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
-
公开(公告)号：US10464995B2
公开(公告)日：2019-11-05
申请号：US15237484
申请日：2016-08-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jonathan Davis , Dasa Lipovsek , Ray Camphausen
Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
-
公开(公告)号：US10266578B2
公开(公告)日：2019-04-23
申请号：US15891492
申请日：2018-02-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
Patent Agency Ranking
公开(公告)号：US09856309B2
公开(公告)日：2018-01-02
申请号：US14956698
申请日：2015-12-02
Applicant: Bristol-Myers Squibb Company
Inventor： Ray Camphausen , Jonathan H. Davis , Sharon T. Cload , Fabienne M. Denhez , Amna Saeed-Kothe , Dasa Lipovsek , Ching-Hsiung Frederick Lo , Chee Meng Low , Bowman Miao , Tracy S. Mitchell , Rex A. Parker , Ginger C. Rakestraw , Katie A. Russo , Doree F. Sitkoff
CPC classification number: C07K14/78 , A61K38/39 , A61K47/549 , A61K47/60 , C07K16/18 , C07K16/40 , C07K2318/20 , C07K2319/30 , C07K2319/31 , C07K2319/70 , C12N9/6424
Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
-
公开(公告)号：US09662373B2
公开(公告)日：2017-05-30
申请号：US14632436
申请日：2015-02-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Alexander T. Kozhich , Martin J. Corbett
IPC: A61K39/395 , A61K38/39 , A61K47/48 , A61K38/17
CPC classification number: A61K38/39 , A61K38/00 , A61K38/17 , A61K38/1709 , A61K45/06 , A61K47/60 , A61K47/642 , C07K14/435 , C07K14/765 , C07K14/78 , C07K14/79 , C07K16/18 , C07K16/46 , C07K2319/30 , C07K2319/31 , G01N33/74
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
-
公开(公告)号：US09631004B2
公开(公告)日：2017-04-25
申请号：US15215329
申请日：2016-07-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
CPC classification number: A61K38/1825 , A61K38/00 , A61K45/06 , A61K47/60 , A61K47/64 , C07K14/50 , C07K2319/00 , C07K2319/30
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
公开(公告)号：US09522951B2
公开(公告)日：2016-12-20
申请号：US14355155
申请日：2012-10-31
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jonathan Davis , Dasa Lipovsek , Ray Camphausen
CPC classification number: C07K14/78 , A61K38/00 , C07K14/47 , C07K16/241 , C07K16/244 , C07K16/28 , C07K16/2833 , C07K16/2857 , C07K2317/92 , C07K2318/20 , C12N15/1062 , C40B40/10 , G01N33/68 , G01N33/6887
Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
Abstract translation: 提供了具有与降低的免疫原性相关的新颖设计的纤连蛋白III型（10Fn3）结合结构域。 本申请描述了替代的10Fn3结合结构域，其中当产生粘合剂时，某些免疫原性区域不被修饰，以便由宿主生物保持识别为自身抗原。 该应用还描述了其中HLA锚定区已经被破坏的10Fn3结合结构域，从而降低相邻区域的免疫原性贡献。 还提供了10Fn3结构域，其具有可以高亲和力结合所需靶的修饰区域的新颖组合。
-
公开(公告)号：US09493546B2
公开(公告)日：2016-11-15
申请号：US14481641
申请日：2014-09-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Hui Wei , Aaron P. Yamniuk , Vidhyashankar Ramamurthy , Alexander T. Kozhich , Martin J. Corbett , Stanley Richard Krystek, Jr.
IPC: A61K38/00 , C07K1/00 , C07K14/00 , C07K17/00 , C07K16/00 , C12P21/08 , A61K35/14 , C07K14/78 , C07K16/46 , A61K38/39 , A61K47/48 , A61K45/06 , G01N33/74 , C07K14/435 , C07K14/765 , C07K14/79 , C07K16/18 , A61K38/17
CPC classification number: A61K38/39 , A61K38/00 , A61K38/17 , A61K38/1709 , A61K45/06 , A61K47/60 , A61K47/642 , C07K14/435 , C07K14/765 , C07K14/78 , C07K14/79 , C07K16/18 , C07K16/46 , C07K2319/30 , C07K2319/31 , G01N33/74
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
-
-
-
-
-
-
-
-
-
Search Results
67
records
(took 0.042 seconds)
